Favorable clinical course after early-intensive immunotherapy for new-onset refractory status epilepticus
Open Access
- 15 June 2020
- journal article
- Published by Korean Neurocritical Care Society in Journal of Neurocritical Care
- Vol. 13 (1) , 65-68
Abstract
Background: New-onset refractory status epilepticus (NORSE) refers to the newly established concept of a disease characterized by refractory status epilepticus without an identifiable etiology. Recent reports have indicated the importance of immunotherapy for NORSE. Case Report: A 37-year-old man with no past history of epilepsy was admitted for a presenting complaint of confusion. He was treated with acyclovir and anti-epileptic drug (AED) for presumed herpes encephalitis. However, he developed generalized tonic-clonic seizures on day 6 of admission that worsened despite treatment with multiple AEDs. NORSE was considered to be a probable diagnosis and immunotherapy with methylprednisolone and immunoglobulin was scheduled. However, persistent seizure activity was observed on the electroencephalogram after the completion of initial immunotherapy. Subsequently, rituximab was administered for 4 weeks. He eventually regained consciousness and was able to resume social activity. Conclusion: Our patient exhibited a favorable outcome with early-intensive immunotherapy and subsequent rituximab treatment for NORSE.Keywords
Funding Information
- Pusan National University
This publication has 11 references indexed in Scilit:
- Systematic Review: Syndromes, Early Diagnosis, and Treatment in Autoimmune EncephalitisFrontiers in Neurology, 2018
- Management of Autoimmune Status EpilepticusFrontiers in Neurology, 2018
- New‐onset refractory status epilepticus (NORSE) and febrile infection–related epilepsy syndrome (FIRES): State of the art and perspectivesEpilepsia, 2018
- Clinical characterization of unknown/cryptogenic status epilepticus suspected as encephalitis: A multicenter cohort studyJournal of Neuroimmunology, 2018
- Rituximab treatment for autoimmune limbic encephalitis in an institutional cohortNeurology, 2016
- New-onset refractory status epilepticusNeurology, 2015
- Predictors of Outcome in Refractory Status EpilepticusJAMA Neurology, 2013
- Predictors of Outcome in Refractory Status EpilepticusJAMA Neurology, 2012
- B cells as therapeutic targets in autoimmune neurological disordersNature Clinical Practice Neurology, 2008
- Refractory Status EpilepticusArchives of Neurology, 2002